Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Doctors’ Lobby Voices Opposition to Changing Health Coverage, Copay Rates for Minor Illnesses
June 6, 2019
- Ahead of G20 Summit, Global Pharma Leaders Prod PM Abe to Take Leadership in Addressing Health Challenges
June 5, 2019
- Generic Industry Calls for Support for API Purchase Cost, Revision of Gx Pricing: LDP Study Group
June 3, 2019
- JPMA Asks Govt to Buy 1.3 Billion Yen Cryo-EM Equipment to Fuel Drug Discovery
May 29, 2019
- JPWA Pushing for September Announcement of New NHI Prices
May 27, 2019
- Medipal Pres. Watanabe Elected as New JPWA Chief
May 24, 2019
- Professor Calls for More Balanced Healthcare Resource Allocation, Higher Copay for Minor Illnesses
May 24, 2019
- Hodanren Renews Call for Transparent Pricing for Kymriah
May 23, 2019
- OTC Industry Group to Up Its Efforts to Reduce “Switch Lag”
May 22, 2019
- Sales of Japan CRO Association Members Down 1.2% to 190 Billion Yen in 2018; Pharma Sales Up 2.6%
May 22, 2019
- Wholesaler Group to Set Up Own Rules for Information Provision by Autumn
May 21, 2019
- Kymriah’s 33.5 Million Yen Price Tag Favorably Received by JMA
May 16, 2019
- Payer Reps Stress Need to Revise Coverage of Drugs for Minor Illnesses; Kymriah’s Price Isn’t Necessarily too High
May 16, 2019
- Number of Contract Sales Reps Down 11.5% in FY2018: JCSOA
April 19, 2019
- GHIT Fund to Leverage Japanese Technology to Benefit Neglected Patients around the World: New CEO
April 18, 2019
- Regenerative Medicine Groups in Asia Begin Discussions towards Mutual Approval
April 15, 2019
- JPMA Not Envisioning Asia-Version EMA at This Point: Chief
April 11, 2019
- Drug Damage Watchdog Nudges Govt, Shionogi to Suspend Xofluza Sales
April 10, 2019
- Vaccine Heavyweight Prods Japan to Expedite Recommendation Process for Immunization Program, Ensure Funding
April 9, 2019
- Patient Groups Press for Emergency Import of Methotrexate amid Tight Supply
April 8, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…